thalidomide has been researched along with Thrombocythemia in 9 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "As lenalidomide has shown to be efficacious in both myelodysplastic syndromes and myeloproliferative neoplasms, we have treated 2 RARS-T patients, who were transfusion dependent, with lenalidomide." | 5.36 | Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis. ( de Wolf, JT; Huls, G; Mulder, AB; Rosati, S; van de Loosdrecht, AA; Vellenga, E, 2010) |
| "Changes in peripheral blood platelet counts associated with the onset of symptomatic erythema nodosum leprosum (ENL) were studied by comparing, in each patient, the value obtained on the day thalidomide therapy commenced with the average of the three preceding values." | 3.71 | Elevated platelet counts and thrombocytosis in erythema nodosum leprosum. ( Rea, TH, 2002) |
| "Myelofibrosis with myeloid metaplasia (MMM) is uniquely characterized by macroscopic bone marrow stromal changes that are believed to be both reactive and cytokine mediated." | 2.70 | Thalidomide treatment in myelofibrosis with myeloid metaplasia. ( Ansell, SM; Elliott, MA; Geyer, SM; Hook, CC; Levitt, RM; Li, CY; Mesa, RA; Tefferi, A, 2002) |
| "Anemia and iron overload are complications in both diseases and are managed similar to lower risk MDS." | 2.52 | Refractory anemia with ring sideroblasts and RARS with thrombocytosis. ( Patnaik, MM; Tefferi, A, 2015) |
| "As lenalidomide has shown to be efficacious in both myelodysplastic syndromes and myeloproliferative neoplasms, we have treated 2 RARS-T patients, who were transfusion dependent, with lenalidomide." | 1.36 | Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis. ( de Wolf, JT; Huls, G; Mulder, AB; Rosati, S; van de Loosdrecht, AA; Vellenga, E, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caers, J | 1 |
| Hafraoui, K | 1 |
| Keutgens, A | 1 |
| Caberg, JH | 1 |
| Lambert, F | 1 |
| Tassin, F | 1 |
| Beguin, Y | 1 |
| Patnaik, MM | 1 |
| Tefferi, A | 2 |
| Huls, G | 1 |
| Mulder, AB | 1 |
| Rosati, S | 1 |
| van de Loosdrecht, AA | 1 |
| Vellenga, E | 1 |
| de Wolf, JT | 1 |
| Ziarkiewicz, M | 1 |
| Dwilewicz-Trojaczek, J | 1 |
| Pastwińska, A | 1 |
| Chmarzyńska, E | 1 |
| Paszkowska-Kowalewska, M | 1 |
| Koperski, Ł | 1 |
| Jędrzejczak, WW | 1 |
| Ziarkiewicz-Wróblewska, B | 1 |
| Keel, SB | 1 |
| Phelps, S | 1 |
| Sabo, KM | 1 |
| O'Leary, MN | 1 |
| Kirn-Safran, CB | 1 |
| Abkowitz, JL | 1 |
| Zhang, M | 1 |
| You, Y | 1 |
| Li, X | 1 |
| He, Y | 1 |
| Zheng, J | 1 |
| Li, W | 1 |
| Zou, P | 1 |
| Liu, X | 1 |
| Liu, F | 1 |
| Rea, TH | 1 |
| Kyrtsonis, MC | 1 |
| Kokoris, SI | 1 |
| Kontopidou, FN | 1 |
| Siakantaris, MP | 1 |
| Kittas, C | 1 |
| Pangalis, GA | 1 |
| Elliott, MA | 1 |
| Mesa, RA | 1 |
| Li, CY | 1 |
| Hook, CC | 1 |
| Ansell, SM | 1 |
| Levitt, RM | 1 |
| Geyer, SM | 1 |
1 review available for thalidomide and Thrombocythemia
| Article | Year |
|---|---|
Refractory anemia with ring sideroblasts and RARS with thrombocytosis.
Topics: Anemia, Refractory; Anemia, Sideroblastic; Angiogenesis Inhibitors; Aspirin; Female; Humans; Iron Ov | 2015 |
1 trial available for thalidomide and Thrombocythemia
| Article | Year |
|---|---|
Thalidomide treatment in myelofibrosis with myeloid metaplasia.
Topics: Adult; Aged; Drug Administration Schedule; Female; Hematopoiesis, Extramedullary; Humans; Immunosupp | 2002 |
7 other studies available for thalidomide and Thrombocythemia
| Article | Year |
|---|---|
Haematological and molecular responses in refractory anaemia with ring sideroblasts and thrombocytosis treated with lenalidomide.
Topics: Aged, 80 and over; Anemia, Refractory; Bone Marrow; Erythrocytes, Abnormal; Female; Humans; Immunolo | 2014 |
Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.
Topics: Aged, 80 and over; Anabolic Agents; Anemia, Refractory; Anemia, Sideroblastic; Antineoplastic Agents | 2010 |
Refractory anaemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) with superimposed 5q-syndrome.
Topics: Aged; Anemia, Macrocytic; Anemia, Refractory; Anemia, Sideroblastic; Antineoplastic Agents; Bone Mar | 2010 |
Establishing Rps6 hemizygous mice as a model for studying how ribosomal protein haploinsufficiency impairs erythropoiesis.
Topics: Agranulocytosis; Alleles; Anemia, Diamond-Blackfan; Anemia, Macrocytic; Animals; Chromosome Deletion | 2012 |
Response to lenalidomide of a patient with t(2;3)(p23;q29) and JAK2 non-mutated refractory anemia with ring sideroblasts and thrombocytosis.
Topics: Adult; Anemia, Refractory; Bone Marrow; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 3; Fema | 2013 |
Elevated platelet counts and thrombocytosis in erythema nodosum leprosum.
Topics: Adult; Erythema Nodosum; Female; Humans; Leprostatic Agents; Leprosy, Lepromatous; Male; Mexico; Mid | 2002 |
Development of a myeloproliferative disorder in a patient with monoclonal gammopathy of undetermined significance secreting immunoglobulin of the M class and treated with thalidomide and anti-CD20 monoclonal antibody.
Topics: Aged; Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Disease Progression; Humans; Im | 2001 |